glp-1 receptor agonists energy fatigue effects 2025 Glucagon-like peptide-1 and muscle mass I'm often asked about GLP-1

Abstract Purpose of Review The purpose of this review is two-fold: (1) to discuss a case report of idiopathic intracranial hypertension (IIH) after abrupt cessation of a glucagon-like peptide-1 (GLP-1) receptor agonist with resultant rapid weight gain and (2) to review the literature regarding the potential role of GLP-1 receptor agonists in the treatment of IIH as well as potential pitfalls

This trial, ATTAIN-2, was a double-blind 72-week trial in 136 sites across 10 countries

Here is the short answer: it depends on your concentration

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression

Recovery Dynamics and Prognosis After Dialysis for Acute Kidney Injury

This agent differs from earlier therapies that were designed to reduce myocardial loading or induce neurohumoral blockade